- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-24
DOI
10.3389/fphar.2021.790963
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decorin as a possible strategy for the amelioration of COVID-19
- (2021) Prince Allawadhi et al. MEDICAL HYPOTHESES
- It’s all about the spaces between cells: role of extracellular matrix in liver fibrosis
- (2021) Amit Khurana et al. Annals of Translational Medicine
- The Role of PD-1 in Acute and Chronic Infection
- (2020) Jil M. Jubel et al. Frontiers in Immunology
- Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
- (2020) Youhai Jiang et al. Frontiers in Immunology
- Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
- (2020) Bin Li et al. Frontiers in Immunology
- Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
- (2019) Masatoshi Kudo WORLD JOURNAL OF GASTROENTEROLOGY
- Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis
- (2019) Jing Zhou et al. IMMUNITY
- JQ1, a BET‐bromodomain inhibitor, inhibits human cancer growth and suppresses PD‐L1 expression
- (2019) Kaisheng Liu et al. CELL BIOLOGY INTERNATIONAL
- Pembrolizumab‐induced mucositis in a patient with recurrent hypopharynx squamous cell cancer
- (2019) Meredith S. Pelster et al. LARYNGOSCOPE
- Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report
- (2019) Lingdi Zhao et al. Immunotherapy
- The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
- (2019) Günther Schönrich et al. Frontiers in Cellular and Infection Microbiology
- CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B
- (2019) Yuejiao Dong et al. BMC IMMUNOLOGY
- Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
- (2019) Di Lu et al. Journal of Immunology Research
- Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
- (2019) Zuzana Macek Jilkova et al. Cancers
- PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
- (2018) Tricia R. Cottrell et al. CANCER JOURNAL
- Toxicities Associated With PD-1/PD-L1 Blockade
- (2018) Daniel Y. Wang et al. CANCER JOURNAL
- Immune checkpoint blockade for the treatment of human hepatocellular carcinoma
- (2018) Naoshi Nishida et al. HEPATOLOGY RESEARCH
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- PD-1/PD-L1 in disease
- (2018) Nyanbol Kuol et al. Immunotherapy
- Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function
- (2018) Peter T. Sage et al. JOURNAL OF IMMUNOLOGY
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
- (2018) Yiting Wang et al. Frontiers in Pharmacology
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
- (2018) Ritu Shrestha et al. Frontiers in Oncology
- PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
- (2018) Fatemeh K. Dermani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- PD-1 and cancer: molecular mechanisms and polymorphisms
- (2017) Arash Salmaninejad et al. IMMUNOGENETICS
- Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis
- (2017) Hyosun Cho et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4
- (2017) Xin Chen et al. PATHOLOGY RESEARCH AND PRACTICE
- Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma
- (2017) Xiaomeng Dai et al. Translational Oncology
- Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
- (2017) Hae Il Jung et al. Cancer Research and Treatment
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Atezolizumab in invasive and metastatic urothelial carcinoma
- (2017) Michael Crist et al. Expert Review of Clinical Pharmacology
- PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
- (2017) Zijun Y. Xu-Monette et al. Frontiers in Immunology
- Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
- (2017) Xiaofang Xing et al. OncoImmunology
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- PD-1/PD-L1 blockage in cancer treatment—from basic research to clinical application
- (2016) Masaki Mandai International Journal of Clinical Oncology
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
- (2016) Junzo Hamanishi et al. International Journal of Clinical Oncology
- CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation
- (2016) Chang Xian Li et al. JOURNAL OF HEPATOLOGY
- Essential role of HDAC6 in the regulation of PD-L1 in melanoma
- (2016) M. Lienlaf et al. Molecular Oncology
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy
- (2015) C. Li et al. EMBO Molecular Medicine
- Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
- (2015) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism
- (2015) Victor Tkachev et al. JOURNAL OF IMMUNOLOGY
- PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
- (2015) Mei Ji et al. Journal of Translational Medicine
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
- (2015) Roberto Bellucci et al. OncoImmunology
- Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
- (2014) Miguel F. Sanmamed et al. CANCER JOURNAL
- The PD-1/PD-Ls pathway and autoimmune diseases
- (2014) Suya Dai et al. CELLULAR IMMUNOLOGY
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection
- (2014) Matthew M. Staron et al. IMMUNITY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the PD-1 Pathway in the Immune Response
- (2012) L. V. Riella et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Viral acute lower respiratory infections impair CD8+ T cells through PD-1
- (2012) John J. Erickson et al. JOURNAL OF CLINICAL INVESTIGATION
- Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
- (2012) G. Xiao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells
- (2011) Ben Youngblood et al. IMMUNITY
- The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion
- (2011) Kimberly A. Hofmeyer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma
- (2011) Bao-Ju Wang WORLD JOURNAL OF GASTROENTEROLOGY
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection
- (2010) T. Watanabe et al. JOURNAL OF VIRAL HEPATITIS
- Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma
- (2010) Ping-Ning Hsu et al. LIVER INTERNATIONAL
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma
- (2009) Adam J. Gehring et al. GASTROENTEROLOGY
- Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization
- (2008) Nobuhiro Nakamoto et al. GASTROENTEROLOGY
- Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment
- (2008) Simona Urbani et al. JOURNAL OF HEPATOLOGY
- Interaction of human PD-L1 and B7-1
- (2008) Manish J. Butte et al. MOLECULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started